DeviceTalks Podcast Network

Marie Johnson turned tragedy into a mission. In 2002, the CEO of Aum Cardiovascular lost her husband to a sudden heart attack, despite the fact that he was, by all accounts, a perfectly healthy man.

Fast forward 13 years and her company has commercialized a non-invasive test designed to quickly detect significant coronary stenosis called the CADence. Johnson hopes the pre FDA-approved device, which is on the market in Germany, will eliminate needless death due to coronary artery disease.

In this interview, recorded live at our DeviceTalks Minnesota event, touches on Johnson's incredible story.

Marie Johnson turned tragedy into a mission. In 2002, the CEO of Aum Cardiovascular lost her husband to a sudden heart attack, despite the fact that he was, by all accounts, a perfectly healthy man.

Fast forward 13 years and her company has commercialized a non-invasive test designed to quickly detect significant coronary stenosis called the CADence. Johnson hopes the pre FDA-approved device, which is on the market in Germany, will eliminate needless death due to coronary artery disease.

In this interview, recorded live at our DeviceTalks Minnesota event, touches on Johnson's incredible story.

Dr. Manny Villafana is one of the most successful men in the history of medical innovation, having founded four companies, including CPI/Guidant Corp. and St. Jude Medical, Inc.

His most recent venture, Kips Bay Medical was supposed to be his best work yet. However, problems with the FDA and shortfalls on funding doomed the company, which shut down in September 2015.

Recorded live on September 23rd at DeviceTalks Minnesota, just one day after he resigned as CEO of Kips Bay Medical, we discuss failure with Dr. Villafana. How does someone who has had so much success deal with the opposite? What comes next for this serial entrepreneur?

Dr. Manny Villafana is one of the most successful men in the history of medical innovation, having founded four companies, including CPI/Guidant Corp. and St. Jude Medical, Inc.

His most recent venture, Kips Bay Medical was supposed to be his best work yet. However, problems with the FDA and shortfalls on funding doomed the company, which shut down in September 2015.

Recorded live on September 23rd at DeviceTalks Minnesota, just one day after he resigned as CEO of Kips Bay Medical, we discuss failure with Dr. Villafana. How does someone who has had so much success deal with the opposite? What comes next for this serial entrepreneur?

Stephen Marsh has more than 70 patents to his name but his most recent endeavor, the Airing device, may make him a household name. The Airing is a hoseless, maskless, disposable micro CPAP machine, which could one day change the game in sleep apnea. However, Marsh and company have already made quite the mark on medtech by running one of the most successful crowdfunding campaigns ever. The company has raised more than $1 million on Indiegogo, more than 10 times its initial goal.

In this episode of DeviceTalks, we talk to Marsh about the Airing device, inventing technology that sticks and how the company pulled off such a successful crowd funding campaign.

Stephen Marsh has more than 70 patents to his name but his most recent endeavor, the Airing device, may make him a household name. The Airing is a hoseless, maskless, disposable micro CPAP machine, which could one day change the game in sleep apnea. However, Marsh and company have already made quite the mark on medtech by running one of the most successful crowdfunding campaigns ever. The company has raised more than $1 million on Indiegogo, more than 10 times its initial goal.

In this episode of DeviceTalks, we talk to Marsh about the Airing device, inventing technology that sticks and how the company pulled off such a successful crowd funding campaign.

Ten years after it was spun out of MIT, Invivo Thereapeutics and its neuro scaffold treatment for traumatic spinal cord injuries is moving closer to a reality. The company has completed enrollment of its 5 patient pilot study, which has made headlines around the world and is looking to push forward on adding more patients. In this episode of DeviceTalks, we talk to new CEO Mark Perrin about the company and why there has been so little movement in the fight against paralysis.

Ten years after it was spun out of MIT, Invivo Thereapeutics and its neuro scaffold treatment for traumatic spinal cord injuries is moving closer to a reality. The company has completed enrollment of its 5 patient pilot study, which has made headlines around the world and is looking to push forward on adding more patients. In this episode of DeviceTalks, we talk to new CEO Mark Perrin about the company and why there has been so little movement in the fight against paralysis.

In this episode of DeviceTalks, recorded live at our DeviceTalks Boston event at Boston Scientific's corporate headquarters, we sit down with CEO Mike Mahoney to discuss the company's recent turnaround. Mahoney, who joined the company as its CEO in 2012, sat down with MassDevice's Brian Johnson to take us inside how the company has improved its performance.

In this episode of DeviceTalks, recorded live at our DeviceTalks Boston event at Boston Scientific's corporate headquarters, we sit down with CEO Mike Mahoney to discuss the company's recent turnaround. Mahoney, who joined the company as its CEO in 2012, sat down with MassDevice's Brian Johnson to take us inside how the company has improved its performance.